SEATTLE – February 12, 2020 – Proprio, the Seattle firm enabling surgeons to perform complex procedures utilizing proprietary imaging techniques and mixed reality environments for more precise surgical navigation, has emerged from stealth mode and appointed healthcare leader Alan Levy, PhD, to its Board of Directors. Dr. Levy brings to Proprio more than 40 years of senior operational leadership and entrepreneurial experience in the medical device industry.
“We founded Proprio with a vision for the future of medicine in which the best of human and machine capabilities come together to produce excellent surgical outcomes,” said Gabriel Jones, CEO and Co-founder of Proprio. “We’re working with world-class computer scientists, engineers, surgeons, designers, and healthcare business leaders to redesign the operating room, and we are thrilled to now have the valuable expertise of Dr. Levy on our Board of Directors.”
“Over the years I have been privileged to work with and lead transformative companies in the healthcare sector,” said Dr. Levy. “I enjoy the challenge and opportunity of building a product that will have a significant impact on the lives of patients and practitioners alike, and I’m excited about Proprio’s potential to transform the operating room. I have seen many innovations in healthcare and Proprio has great potential to make a substantial impact.”
Most recently Dr. Levy served as the Chief Executive Officer and Chairman of the Board at Chrono Therapeutics. Additionally, he was a Senior Advisor and Venture Partner at Frazier Healthcare Partners, a top venture capital firm, focusing on the Life Science sector.
Dr. Levy's notable previous leadership experiences include serving as the founding Chief Executive Officer at Incline Therapeutics, acquired by The Medicines Company for $390 million, Chief Executive Officer and President at Northstar Neuroscience, which raised $112 million in their IPO, Chief Executive Officer and President at Heartstream, acquired by Hewlett-Packard for $140 million, and President at Heart Technology, acquired by Boston Scientific for $500 million. In addition, he held several leadership positions at Ethicon, a division of Johnson & Johnson, including Vice President of Research and New Business Development and Director.
Dr. Levy serves as a board member at several public and private companies including Intuitive Surgical, Proteus Digital Health, and Bardy Diagnostics. He received his PhD in organic chemistry from Purdue University, a bachelor’s degree in chemistry from City University of New York, and holds an honorary doctor of science from Purdue University.
Proprio integrates the emerging capabilities of robotics, computer vision, machine learning, and immersive computing to enhance the combined performance of human and machine in healthcare.
Proprio is backed by leading healthcare and technology investors, including BOLD Capital Partners, Intel, HTC, L2 Ventures, and Alan Frazier, founder of East Seattle Partners and Frazier Healthcare Partners.
For more information visit www.propriovision.com.
October 30, 2019